Pharvaris N.V. (NASDAQ:PHVS) Receives $36.20 Average Target Price from Analysts

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) has been given a consensus rating of "Buy" by the five analysts that are presently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have issued a report on the stock in the last year is $36.20.

A number of brokerages recently issued reports on PHVS. Cantor Fitzgerald lowered their price target on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Guggenheim began coverage on Pharvaris in a report on Wednesday, June 11th. They issued a "buy" rating and a $32.00 price target for the company. Finally, Wedbush reiterated an "outperform" rating and issued a $27.00 price target on shares of Pharvaris in a report on Thursday, June 5th.

Hedge Funds Weigh In On Pharvaris

A number of large investors have recently bought and sold shares of the business. Legal & General Group Plc increased its position in shares of Pharvaris by 11.2% during the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock worth $189,000 after purchasing an additional 994 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Pharvaris by 3.7% during the fourth quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock worth $735,000 after purchasing an additional 1,356 shares in the last quarter. Deutsche Bank AG increased its position in shares of Pharvaris by 13.0% during the fourth quarter. Deutsche Bank AG now owns 18,168 shares of the company's stock worth $348,000 after purchasing an additional 2,087 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after purchasing an additional 2,847 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Pharvaris in the 4th quarter valued at $64,000.

Pharvaris Price Performance

Shares of NASDAQ:PHVS traded up $0.52 during trading hours on Friday, hitting $18.50. 45,346 shares of the company's stock traded hands, compared to its average volume of 70,677. Pharvaris has a 1 year low of $11.51 and a 1 year high of $25.50. The business has a fifty day moving average price of $17.09 and a 200-day moving average price of $16.66. The firm has a market capitalization of $967.37 million, a P/E ratio of -6.15 and a beta of -2.82.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.09). As a group, equities analysts predict that Pharvaris will post -2.71 earnings per share for the current year.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.